4,357
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Novartis's recently active trials. Comparator arms are excluded.
- Remibrutinib7 trials
- Ianalumab4 trials
- trametinib3 trials
- Ruxolitinib3 trials
- 68Ga-PSMA-113 trials
- Fulvestrant3 trials
Upcoming readouts
Next primary completion dates among Novartis's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Feb 2027PLATINUM: Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With …Phase 2
- Feb 2027ACS: Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Pat…Phase 3
- Mar 2027Study of Out of Specification for TisagenlecleucelPhase 3
- Apr 2027A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatr…Phase 2
- Jul 2027A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fe…Phase 2
- Jul 2027A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.Phase 2
Top therapeutic areas
Conditions studied most often across Novartis's recently active trials.
- Breast Cancer3 trials
- Primary Myelofibrosis (PMF)2 trials
- Sickle Cell Disease2 trials
- Chagas Disease2 trials
- Primary Immune Thrombocytopenia (ITP)2 trials
- Prostate Cancer2 trials
Novartis pipeline by phase
The main study drugs across 315 active trials Novartis leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 331 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| IanalumabVAY736 | 17 | 6 | Oct 2026 est. | NCT07621809 · NCT06711887 · NCT06133972 |
| Remibrutinib | 16 | 7 | Nov 2026 est. | NCT07816328 · NCT07811869 · NCT07768371 |
| IptacopanLNP023 | 13 | 9 | Dec 2026 est. | NCT06994845 · NCT06934967 · NCT06517758 |
| Alpelisib | 9 | 2 | Jan 2027 est. | NCT05038735 · NCT04208178 · NCT07679269 |
| Pelabresib | 7 | 4 | Nov 2026 est. | NCT07357727 · NCT06401356 · NCT04603495 |
| Pelacarsen | 6 | 4 | Feb 2028 est. | NCT07625306 · NCT07517263 · NCT06875973 |
| OpnurasibJDQ443 | 5 | 1 | Sept 2026 est. | NCT05132075 · NCT05445843 · NCT07468071 |
| TisagenlecleucelCTL019 | 5 | 3 | Mar 2027 est. | NCT05888493 · NCT04094311 · NCT03876769 |
| Lutathera | 4 | — | Mar 2028 est. | NCT03972488 · NCT04711135 · NCT05142696 |
| Asciminib | 3 | — | — | NCT05456191 · NCT04971226 · NCT05384587 |
| ZigakibartBION-1301 | 3 | 2 | Aug 2027 est. | NCT06858319 · NCT05852938 · NCT07146906 |
| AAA817 | 2 | 2 | Jun 2028 est. | NCT06855277 · NCT06780670 |
| Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free | 2 | — | Jan 2027 est. | NCT07578363 · NCT07531043 |
| Atrasentan | 2 | — | Apr 2028 est. | NCT04573478 · NCT04573920 |
| Inclisiran sodium 300 mg | 2 | — | Oct 2026 est. | NCT05360446 · NCT05030428 |
| NIO752 | 2 | 1 | Jul 2029 est. | NCT07498426 · NCT05469360 |
| Remibrutinib (Blinded) | 2 | 2 | Feb 2028 est. | NCT07225504 · NCT06744920 |
| Abelacimab | 1 | — | Dec 2030 est. | NCT07739888 |
| Crizanlizumab (SEG101) | 1 | — | — | NCT03814746 |
| Drug: Atrasentan | 1 | 1 | Sept 2031 est. | NCT07498335 |
| inclisiran sodium | 1 | — | — | NCT04765657 |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | 1 | — | Apr 2029 est. | NCT05739383 |
| Octreotide LAR | 1 | 1 | Dec 2028 est. | NCT06784752 |
| Ofatumumab new dose | 1 | — | — | NCT06869785 |
| onasemnogene abeparvovec | 1 | — | Apr 2031 est. | NCT05335876 |
| Onasemnogene Abeparvovec-xioi | 1 | — | Dec 2035 est. | NCT04042025 |
| Previously treated CAR-T patients | 1 | 1 | Feb 2036 est. | NCT02445222 |
| QMF149 | 1 | 1 | Feb 2028 est. | NCT05562466 |
| QVM149 | 1 | 1 | Dec 2028 est. | NCT05776927 |
| Remibrutinib oral treatment | 1 | 1 | Jul 2029 est. | NCT06846281 |
| Votoplam (blinded) | 1 | 1 | Apr 2030 est. | NCT07326709 |
Phase 230 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Rapcabtagene autoleucelYTB323 | 7 | — | Sept 2026 est. | NCT06868290 · NCT06665256 · NCT06655896 |
| GIA632 | 3 | 2 | May 2027 est. | NCT07775924 · NCT07431177 · NCT07220577 |
| JSB462 | 3 | — | Jan 2027 est. | NCT07047118 · NCT06991556 · NCT07174063 |
| QCZ484 | 3 | 2 | Jan 2027 est. | NCT07610278 · NCT07543120 · NCT06857955 |
| DDY391 | 2 | 1 | Dec 2028 est. | NCT07801495 · NCT07737743 |
| MAS825 | 2 | 1 | Apr 2027 est. | NCT07203001 · NCT04641442 |
| PKN605 | 2 | 1 | Feb 2027 est. | NCT07217067 · NCT07797322 |
| VHB937 | 2 | 1 | Sept 2028 est. | NCT07094516 · NCT06643481 |
| ABL001/Asciminib | 1 | 1 | Feb 2029 est. | NCT06514534 |
| Arumakimig | 1 | — | Dec 2028 est. | NCT07748624 |
| Capmatinib | 1 | — | Jul 2027 est. | NCT03040973 |
| CFZ533 | 1 | — | — | NCT03827798 |
| Cryptosporidium parvum oocysts (ABO809) | 1 | 1 | Mar 2027 est. | NCT07249463 |
| decitabine | 1 | — | Feb 2028 est. | NCT05201066 |
| DII235 | 1 | — | Apr 2027 est. | NCT07235046 |
| Eltrombopag | 1 | — | — | NCT04797000 |
| EYU688 | 1 | 1 | Jul 2027 est. | NCT06006559 |
| FWY003 | 1 | 1 | Aug 2029 est. | NCT07441642 |
| GHZ339 | 1 | 1 | Nov 2028 est. | NCT06947993 |
| Glycopyrronium bromide 25ug | 1 | 1 | Jul 2027 est. | NCT05222529 |
| GXV813 | 1 | 1 | Jul 2027 est. | NCT07467993 |
| INE963 | 1 | 1 | — | NCT05750628 |
| Iptacopan (LNP023) | 1 | — | Oct 2026 est. | NCT05230537 |
| KAE609 | 1 | 1 | Feb 2027 est. | NCT07811908 |
| LOU064 | 1 | 1 | Dec 2027 est. | NCT07681271 |
| LXE408 | 1 | 1 | Jul 2027 est. | NCT06632600 |
| LXH254 | 1 | — | Feb 2027 est. | NCT04417621 |
| Midostaurin | 1 | — | May 2029 est. | NCT03591510 |
| TOUR006 - 20 MG | 1 | — | — | NCT06088979 |
| Votoplam | 1 | — | Jul 2029 est. | NCT06254482 |
Phase 146 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| PIT565 | 3 | — | Jan 2027 est. | NCT07029555 · NCT06335979 · NCT05397496 |
| [68Ga]Ga-DWJ155 | 2 | 2 | Jun 2028 est. | NCT07801508 · NCT07117214 |
| [68Ga]Ga-NeoB | 2 | — | Dec 2026 est. | NCT06247995 · NCT05870579 |
| rapcabtagene autoleucel (YTB323) | 2 | — | Jun 2030 est. | NCT06675864 · NCT06617793 |
| Tulmimetostat | 2 | 2 | Feb 2030 est. | NCT07190300 · NCT04104776 |
| [177Lu]Lu-DWJ155 | 1 | 1 | May 2032 est. | NCT07660055 |
| [177Lu]Lu-NeoB | 1 | — | Nov 2028 est. | NCT05739942 |
| [68Ga]Ga-NNS309 | 1 | 1 | Jan 2031 est. | NCT06562192 |
| [68Ga]Ga-PSMA-11 | 1 | — | — | NCT06379217 |
| 225^Ac-PSMA-617 | 1 | — | Jan 2027 est. | NCT04597411 |
| 225Ac-ETN029 | 1 | 1 | Aug 2031 est. | NCT07006727 |
| 225Ac-PSMA-R2 | 1 | — | Mar 2031 est. | NCT05983198 |
| 68Ga-DFC413 | 1 | 1 | Jan 2028 est. | NCT07630961 |
| 68Ga-FAP-2286 | 1 | 1 | Dec 2027 est. | NCT04939610 |
| 68Ga-NNS309 | 1 | 1 | May 2029 est. | NCT07261631 |
| AMO959 | 1 | 1 | Jul 2028 est. | NCT07226986 |
| AR-14034 SR implant lower dose | 1 | — | Apr 2027 est. | NCT05769153 |
| ARV-766 | 1 | — | May 2027 est. | NCT05067140 |
| Asciminib Adult formulation | 1 | 1 | Sept 2033 est. | NCT07387926 |
| Asciminib Pediatric formulation group | 1 | 1 | Sept 2027 est. | NCT04925479 |
| Ceritinib (LDK378) | 1 | — | Apr 2027 est. | NCT02393625 |
| DCY636 | 1 | 1 | Jan 2028 est. | NCT07604324 |
| DFT383 | 1 | 1 | May 2031 est. | NCT06910813 |
| DFV890 | 1 | — | Feb 2027 est. | NCT05552469 |
| DJI136 | 1 | 1 | Mar 2031 est. | NCT07564401 |
| DKY709 | 1 | — | Oct 2026 est. | NCT03891953 |
| DYP688 | 1 | — | Oct 2027 est. | NCT05415072 |
| ECI830 | 1 | 1 | Sept 2028 est. | NCT06726148 |
| EDK060, dose A | 1 | 1 | Feb 2028 est. | NCT07140614 |
| EGF816 | 1 | — | Oct 2026 est. | NCT03333343 |
| GVV858 | 1 | 1 | May 2031 est. | NCT07288359 |
| HJB647 | 1 | 1 | Dec 2026 est. | NCT07644364 |
| HJB647 low dose | 1 | 1 | Sept 2026 est. | NCT07465653 |
| HRO761 | 1 | — | Aug 2027 est. | NCT05838768 |
| IAG933 | 1 | — | Jan 2027 est. | NCT04857372 |
| IDH305 | 1 | — | — | NCT02381886 |
| IEV407 | 1 | 1 | Jun 2032 est. | NCT07604571 |
| INR731 | 1 | 1 | Jun 2030 est. | NCT07570979 |
| ITU512 | 1 | 1 | May 2028 est. | NCT06546670 |
| KFA115 | 1 | — | Sept 2027 est. | NCT05544929 |
| LTP | 1 | 1 | Nov 2028 est. | NCT06649110 |
| OJR520 | 1 | 1 | Jan 2028 est. | NCT07235059 |
| OTQ923 | 1 | — | Jan 2039 est. | NCT06155500 |
| PDR001 | 1 | — | Apr 2030 est. | NCT04058756 |
| Rapcabtagene autoleucel single agent | 1 | — | Jun 2027 est. | NCT03960840 |
| Tulmimetostat DL1 QD | 1 | 1 | Nov 2029 est. | NCT07206056 |
Phase 421 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| inclisiran | 11 | 6 | Oct 2026 est. | NCT07684469 · NCT07102628 · NCT06597019 |
| 177Lu-PSMA-617AAA617 | 9 | 3 | Oct 2026 est. | NCT05803941 · NCT05939414 · NCT04720157 |
| RibociclibLEE011 | 9 | 4 | Feb 2027 est. | NCT05161195 · NCT05827081 · NCT03701334 |
| Secukinumab | 4 | 2 | Feb 2028 est. | NCT07489573 · NCT05622708 · NCT06331312 |
| dabrafenib | 3 | 1 | Nov 2026 est. | NCT03975829 · NCT03340506 · NCT04940052 |
| Ofatumumab | 3 | — | Apr 2027 est. | NCT05090371 · NCT04926818 · NCT03650114 |
| Ruxolitinib | 3 | 1 | May 2029 est. | NCT06824103 · NCT06462469 · NCT02386800 |
| Asciminib single agent | 2 | 2 | Aug 2030 est. | NCT04877522 · NCT07354074 |
| atorvastatin | 2 | 1 | Dec 2026 est. | NCT06372925 · NCT06858332 |
| Crizanlizumab | 2 | 2 | Jul 2029 est. | NCT04657822 · NCT06439082 |
| everolimus | 2 | — | Oct 2026 est. | NCT05252585 · NCT02962414 |
| Fingolimod | 2 | 1 | Sept 2027 est. | NCT04480853 · NCT01892722 |
| ceritinib | 1 | — | Jun 2027 est. | NCT02584933 |
| Coartem® Baby | 1 | — | May 2028 est. | NCT07713602 |
| Educational Material | 1 | 1 | May 2027 est. | NCT07034690 |
| ETNATM-ProgMS | 1 | 1 | Nov 2028 est. | NCT06733922 |
| inclisiran sodium injection | 1 | — | Apr 2027 est. | NCT06941792 |
| Ofatunumab | 1 | — | — | NCT06444113 |
| Onasemnogene Abeparvovec-brve | 1 | — | May 2032 est. | NCT07448610 |
| Secukinumab s.c. injection | 1 | 1 | Jan 2030 est. | NCT04638647 |
| Usual care | 1 | 1 | Nov 2026 est. | NCT06501443 |
Derived from 315 active trials Novartis leads; 286 name an intervention, folding into 128 phased drugs. 12 interventions carry no registry phase (observational studies, tests and devices) and are not shown. This is ComplyRx's reading of the registry, not Novartis's own pipeline disclosure.
Novartis trials
The 50 most significant of Novartis's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection FractionNCT07465653HJB647 low dose | Phase 1 | Locked · track to reveal | OngoingRecruiting | 12 est. | 24 Sept 2026 |
| A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and JapanNCT07821411 | — | Not yet scored | OngoingActive, not recruiting | 5,000 est. | 30 Sept 2026 |
| Feasibility Study of an Accommodating IOL DesignNCT07147192AAL-FAIOL | Na | Locked · track to reveal | OngoingActive, not recruiting | 85 est. | Oct 2026 |
| Pediatric Long-Term Follow-up and Rollover StudyNCT03975829dabrafenib | Phase 4 | Locked · track to reveal | OngoingActive, not recruiting | 163 est. | 5 Nov 2026 |
| Clinical Study of a Fluid Accommodating Intraocular Lens (IOL) DesignNCT05317728BAL-FAIOL IOL | Na | Locked · track to reveal | OngoingActive, not recruiting | 175 est. | Nov 2026 |
| SMA-REALA Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi ArabiaNCT07737756 | — | Not yet scored | OngoingNot yet recruiting | 6 est. | 20 Nov 2026 |
| ROUTE-C3GA Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in SpainNCT07598448 | — | Not yet scored | OngoingNot yet recruiting | 35 est. | 15 Dec 2026 |
| PSMACareA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPCNCT05849298AAA617 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 49 est. | 23 Dec 2026 |
| [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerNCT05870579[68Ga]Ga-NeoB | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 28 est. | 30 Dec 2026 |
| ScreenXModifying PEST for Psoriatic Arthritis ScreeningNCT06382051PEST Screening group | Na | Locked · track to reveal | OngoingRecruiting | 502 est. | 31 Dec 2026 |
| Agreement of Two OCT Biometers: A Pilot StudyNCT07782619UNITY DX | — | Not yet scored | OngoingRecruiting | 50 est. | Jan 2027 |
| An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in AdultsNCT07578363Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 178 est. | Jan 2027 |
| EPIK-B5Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.NCT05038735Alpelisib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 210 est. | 28 Jan 2027 |
| A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsNCT06857955QCZ484 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 396 est. | 29 Jan 2027 |
| Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesNCT05552469DFV890 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 71 est. | 1 Feb 2027 |
| PLATINUMPlatform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)NCT07811908KAE609 | Phase 2 | Not yet scored | OngoingRecruiting | 120 est. | 4 Feb 2027 |
| ACSEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesNCT07102628Inclisiran | Phase 3 | Locked · track to reveal | OngoingRecruiting | 300 est. | 11 Feb 2027 |
| Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in AdultsNCT07531043Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 230 est. | Feb 2027 |
| A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal FunctionNCT07797322PKN605 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 40 est. | 18 Feb 2027 |
| Study of Out of Specification for TisagenlecleucelNCT04094311CTL019 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 200 est. | 31 Mar 2027 |
| NeoB-Cap1A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.NCT06247995[68Ga]Ga-NeoB | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 20 est. | 14 Apr 2027 |
| A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseaseNCT07203001MAS825 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 30 est. | 22 Apr 2027 |
| A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue FeverNCT06006559EYU688 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 108 est. | 22 Jul 2027 |
| A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.NCT06632600LXE408 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 130 est. | 22 Jul 2027 |
| A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisNCT06470048Ianalumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | 30 Jul 2027 |
| Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneNCT03040973Capmatinib | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 29 est. | 30 Jul 2027 |
| REAL-HTNA Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab EmiratesNCT07465666 | — | Not yet scored | OngoingNot yet recruiting | 500 est. | 15 Aug 2027 |
| Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic UrticariaNCT06865651Remibrutinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 44 est. | 23 Aug 2027 |
| Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid LeukemiaNCT04925479Asciminib Pediatric formulation group | Phase 1 | Locked · track to reveal | OngoingRecruiting | 34 est. | 21 Sept 2027 |
| A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular AnomaliesNCT07767877 | — | Not yet scored | OngoingNot yet recruiting | 200 est. | 29 Oct 2027 |
| A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)NCT07681271LOU064 | Phase 2 | Not yet scored | OngoingRecruiting | 100 est. | 7 Dec 2027 |
| A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)NCT06581198rapcabtagene autoleucel | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 179 est. | 14 Feb 2028 |
| PSMA-DCAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.NCT05939414AAA617 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 450 est. | 25 Apr 2028 |
| A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell DiseaseNCT06546670ITU512 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 161 est. | 1 May 2028 |
| VAY2EXPLOREA Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)NCT07421167ianalumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 164 est. | 9 May 2028 |
| MANIFEST-3A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)NCT07357727Pelabresib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 460 est. | 17 May 2028 |
| VITESSA Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental VitiligoNCT07431177GIA632 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 210 est. | 6 Jun 2028 |
| A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid TumorsNCT07801508[68Ga]Ga-DWJ155 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 66 est. | 30 Jun 2028 |
| Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksNCT07816328Remibrutinib | Phase 3 | Not yet scored | OngoingNot yet recruiting | 382 est. | 17 Jul 2028 |
| EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)NCT06997588Alpelisib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 104 est. | 2 Aug 2028 |
| AcTFirstStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCNCT06855277AAA817 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 940 est. | 29 Sept 2028 |
| Specified Drug-use Surveillance of Fabhalta CapsulesNCT06606314 | — | Not yet scored | OngoingActive, not recruiting | 132 est. | 30 Sept 2028 |
| A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's DiseaseNCT07048197Rapcabtagene autoleucel | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 27 est. | 1 Nov 2028 |
| ELIPSIA Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen PlanusNCT07775924GIA632 | Phase 2 | Not yet scored | OngoingRecruiting | 259 est. | 22 Nov 2028 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisNCT06655896rapcabtagene autoleucel | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 96 est. | 30 Nov 2028 |
| NETTER-3Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETNCT06784752[177Lu]Lu-DOTA-TATE | Phase 3 | Locked · track to reveal | OngoingRecruiting | 240 est. | 8 Dec 2028 |
| A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic ArthritisNCT07801495DDY391 | Phase 2 | Not yet scored | OngoingNot yet recruiting | 220 est. | 13 Dec 2028 |
| A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.NCT05776927QVM149 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 188 est. | 30 Dec 2028 |
| A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's DiseaseNCT07737743DDY391 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 344 est. | 19 Feb 2029 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)NCT07811869Remibrutinib | Phase 3 | Not yet scored | OngoingRecruiting | 180 est. | 26 Feb 2029 |